You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease
SBC: LEFLORE TECHNOLOGIES LLC Topic: 400Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Immersive Virtual Reality as a Tool to Improve Police Safety in Adolescents and Adults with ASD
SBC: Floreo, Inc. Topic: 103Floreo Technology proposes to develop the Police Safety Module PSM an innovative immersive mobile virtual reality VR application designed to train police safety in adolescents and adults with autism spectrum disorder ASD ASD has been increasing in prevalence over recent years While much attention has been paid to the causes and early diagnosis of ASD there remains a clear need for effec ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mutation Enriched Targeted Re Sequencing
SBC: TRANSGENOMIC, INC. Topic: 103DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis
SBC: Sanguine Diagnostics And Therapeutics, Inc. Topic: 103ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer
SBC: ACTORIUS PHARMACEUTICALS, LLC Topic: 100DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
TARGETING STEALTH LIPOSOME FOR CANCER GENE THERAPY
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/AAdvanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents, and this chemoresistance correlates with a lack of functional p53. Our preliminary data indicate that cancer cells can be sensitize to chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. The low stability and rapid clearance from circulation of these ligand-liposomes are ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack of functional p53. Our previous data indicate that cancer cells can be sensitized to radiation and chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. In the STTR Phase ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack of functional p53. Our previous data indicate that cancer cells can be sensitized to radiation and chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. In the STTR Phase ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health